Aster DM Quality Care Ltd reported a robust Q2 FY27, with revenue jumping 19% YoY to INR 2,829 crore and a 34% surge in normalized PAT. The company is capitalizing on operational synergies, achieving 16.6 crore in savings this quarter, and expanding its bed capacity to support long-term growth.
Aster DM Quality Care Q2 Results: Revenue Hits Record INR 2,829 Crore
Operating EBITDA rose 25% to INR 678 crore with margin expansion to 24%.
Reader Takeaway: Strong operational leverage and synergy realization drive profit, while execution risks regarding bed expansion capacity remain critical.
What just happened
Aster DM Quality Care Ltd has posted record-breaking financial results for the second quarter of FY27. Revenue from operations reached INR 2,829 crore, a 19% increase compared to INR 2,382 crore in the same period last year. Normalized Profit After Tax (PAT) surged 34% to INR 281 crore, reflecting improved operating margins and successful cost management.
Why this matters
The company’s performance highlights the effectiveness of its post-merger strategy. With operating EBITDA margins expanding by 111 basis points to 24%, Aster is demonstrating strong operational leverage. The company successfully realized INR 16.6 crore in synergies this quarter alone, part of a larger INR 200 crore target, which remains a key driver for long-term margin improvement.
Operational Performance
Patient volume grew by 12% to 2.18 million, supported by an increase in occupancy rates to 68%. The company is aggressively scaling its infrastructure, now operating 10,611 beds with a clear roadmap to exceed 15,000 beds. Significant capital has been deployed in high-end medical technology, with over INR 600 crore invested in the last 18 months, including the addition of robotics and advanced diagnostic tools.
Geographical Growth
Growth remained broad-based across all core regions:
- Kerala and Tamil Nadu saw a 23% revenue increase to INR 1,216 crore.
- South-West and Central regions grew by 16% to INR 689 crore.
- South-East operations reported a 13% growth, contributing INR 830 crore.
Risks to watch
Investors should closely monitor the execution of the company’s greenfield and brownfield projects as it aims for its 15,000-bed target. Furthermore, potential shifts in payor mix and rising competitive pressures in the hospital sector are factors that could impact future margins.
What to track next
Watch for updates on the pace of synergy realization and the conversion timeline of new bed capacity into revenue-generating assets.